Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Propylthiouracil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPO known ✓ | P07202 | 1/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | LPO | P22079 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6998271 | 0.85 | DAO (0.35) | ALDH1A1KDM4ESMN1; SMN2BACE1HCAR2 | |
| SCHEMBL23542304 | 0.79 | ADORA1 (0.47) | MPOTPOTSHRLPOCYP2C19 | |
| SCHEMBL9879243 | 0.78 | BACE1 (0.54) | MPOTPOTSHRLPOCYP2C19 | |
| SCHEMBL9878843 | 0.75 | ADORA1 (0.44) | MPOTPOTSHRLPOCYP2C19 | |
| SCHEMBL25036350 | 0.74 | ADORA1 (0.46) | MPOTPOTSHRLPOCYP2C19 | |
| SCHEMBL23894726 | 0.71 | ALDH1A1 (0.41) | MPOTPOTSHRLPOCYP2C19 | |
| SCHEMBL27398272 | 0.71 | KMT2A (0.46) | MPOTPOTSHRLPOCYP2C19 | |
| Propylthiouracil SCHEMBL4537771 | 0.70 | BACE1 (0.64) | ALDH1A1HPGDHSD17B10SMN1; SMN2BACE1 | |
| SCHEMBL15332976 | 0.69 | CYP1A2 (0.42) | MPOTPOTSHRLPOCYP2C19 | |
| SCHEMBL23542344 | 0.68 | ALDH1A1 (0.50) | TSHRALDH1A1HSD17B10KDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250064785-A1 | THIOUREYLENE LIQUID COMPOSITIONS | NORBROOK LICENCES LIMITED (IE) | 2025-02-27 | — | — | US | disclosed |
| US-12171749-B2 | Thioureylene liquid compositions | NORBROOK LABORATORIES LIMITED (GB) | 2024-12-24 | — | — | US | disclosed |
| US-12018003-B2 | Substituted pyrimidines as matrix metalloproteinase-9 hemopexin domain inhibitors | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230404978-A1 | THIOUREYLENE LIQUID COMPOSITIONS | NORBROOK LICENCES LIMITED (IE) | 2023-12-21 | — | — | US | disclosed |
| US-11738005-B2 | Thioureylene liquid compositions | NORBROOK LABORATORIES LIMITED (GB) | 2023-08-29 | — | — | US | disclosed |
| EP-3160441-B1 | THIOUREYLENE LIQUID COMPOSITIONS | NORBROOK LAB LTD (GB) | 2022-01-12 | — | — | EP | disclosed |
| US-20210361623-A1 | THIOUREYLENE LIQUID COMPOSITIONS | NORBROOK LICENCES LIMITED (IE) | 2021-11-25 | — | — | US | disclosed |
| US-20210309616-A1 | SUBSTITUTED QUINAZOLINES AS MATRIX METALLOPROTEINASE-9 HEMOPEXIN DOMAIN INHIBITORS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2021-10-07 | — | — | US | disclosed |
| US-11123327-B2 | Thioureylene liquid compositions | NORBROOK LABORATORIES LIMITED (GB) | 2021-09-21 | — | — | US | disclosed |
| EP-3441063-B1 | THIOUREYLENE LIQUID COMPOSITIONS | NORBROOK LAB LTD (GB) | 2021-07-21 | — | — | EP | disclosed |
| US-11040947-B2 | Substituted quinazolines as matrix metalloproteinase-9 hemopexin domain inhibitors | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2021-06-22 | — | — | US | disclosed |
| US-20200405690-A1 | THIOUREYLENE LIQUID COMPOSITIONS | NORBROOK LICENCES LIMITED (IE) | 2020-12-31 | — | — | US | disclosed |
| EP-3441063-A1 | THIOUREYLENE LIQUID COMPOSITIONS | Norbrook Laboratories Limited (GB) | 2019-02-13 | — | — | EP | disclosed |
| US-20180318262-A1 | THIOUREYLENE LIQUID COMPOSITIONS | NORBROOK LABORATORIES LIMITED (GB) | 2018-11-08 | — | — | US | disclosed |
| WO-2018175670-A1 | MATRIX METALLOPROTEINASE-9 HEMOPEXIN DOMAIN INHIBITORS AND METHODS OF TREATMENT USING SAME | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2018-09-27 | — | — | WO | disclosed |
| US-20170135987-A1 | THIOUREYLENE LIQUID COMPOSITIONS | NORBROOK LICENCES LIMITED (IE) | 2017-05-18 | — | — | US | disclosed |
| EP-3160441-A1 | THIOUREYLENE LIQUID COMPOSITIONS | Norbrook Laboratories Limited (GB) | 2017-05-03 | — | — | EP | disclosed |
| WO-2015198033-A1 | THIOUREYLENE LIQUID COMPOSITIONS | NORBROOK LABORATORIES LIMITED (GB) | 2015-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210361623-A1 | THIOUREYLENE LIQUID COMPOSITIONS | TPO, TSHR, TRHDE | TPO 1/4885MPO 750/4885TSHR 2/4885 |
| US-20230404978-A1 | THIOUREYLENE LIQUID COMPOSITIONS | TPO, TSHR, TRHDE | TPO 1/4885MPO 750/4885TSHR 2/4885 |
| US-20200405690-A1 | THIOUREYLENE LIQUID COMPOSITIONS | TPO, TSHR, TRHDE | TPO 1/4885MPO 750/4885TSHR 2/4885 |
| US-20250064785-A1 | THIOUREYLENE LIQUID COMPOSITIONS | TPO, TSHR, TRHDE | TPO 1/4885MPO 750/4885TSHR 2/4885 |
| US-12018003-B2 | Substituted pyrimidines as matrix metalloproteinase-9 hemopexin domain inhibitors | MMP9, MMP7, MMP11 | TPO 2263/4885MPO 978/4885TSHR 4522/4885 |
| US-20210309616-A1 | SUBSTITUTED QUINAZOLINES AS MATRIX METALLOPROTEINASE-9 HEMOPEXIN DOMAIN INHIBITORS | MMP2, MMP9, MMP10 | TPO 2832/4885MPO 315/4885TSHR 4697/4885 |
| US-11040947-B2 | Substituted quinazolines as matrix metalloproteinase-9 hemopexin domain inhibitors | MMP2, CBR3, NR4A3 | TPO 3240/4885MPO 619/4885TSHR 1312/4885 |
| US-20170135987-A1 | THIOUREYLENE LIQUID COMPOSITIONS | TPO, TSHR, TRHDE | TPO 1/4885MPO 750/4885TSHR 2/4885 |
| US-11738005-B2 | Thioureylene liquid compositions | TPO, TSHR, TRHDE | TPO 1/4885MPO 750/4885TSHR 2/4885 |
| US-11123327-B2 | Thioureylene liquid compositions | TPO, TSHR, TRHDE | TPO 1/4885MPO 750/4885TSHR 2/4885 |
| US-12171749-B2 | Thioureylene liquid compositions | TPO, TSHR, TRHDE | TPO 1/4885MPO 750/4885TSHR 2/4885 |
| US-20180318262-A1 | THIOUREYLENE LIQUID COMPOSITIONS | TPO, TSHR, TRHDE | TPO 1/4885MPO 750/4885TSHR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.